The analyst believes that the Copaxone legal update will be the next major swing factor for TEVA. The analyst participated in calls with TEVA’s SVP, Chief IP Counsel, and an external consultant to gauge where the stock is headed. For the most part, the general attitude towards TEVA’s stock is negative, however, the analyst affirms that focus is set to shift back to Copaxone leaving for favorable risk/reward following lowered expectations.

According to TipRanks, Randall Stanicky is ranked #992 of 4,058 analysts. He maintains a success rate of 51% and an average return of 3.4%. When rating TEVA, the analyst upholds a success rate of 54% and realizes an average profit of -0.9%.